|
|
Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 167)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Melphalan | approved | Phase 3, Phase 1, Phase 2 | 729 | 148-82-3 | 4053, 460612 | (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid 148-82-3 3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine 3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine 3025 C.B. 3025 c.b 3223-07-2 4-(Bis(2-chloroethyl)amino)-L-phenylalanine 4-14-00-01689 (Beilstein Handbook Reference) 4-[Bis(2-chloroethyl)amino]-L-phenylalanine 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine AC1LA2OE ALKERAN (TN) AY3360000 Alanine Nitrogen Mustard Alkeran AmbotzHAA1563 At-290 BIDD:GT0044 BRD-K87827419-001-02-8 BRN 2816456 BSPBio_002407 C13H18Cl2N2O2 CB 3025 CB-3025 CCRIS 374 CHEBI:165415 CHEBI:28876 CHEMBL852 CID460612 D00369 DivK1c_000653 EINECS 205-726-3 HMS2090B09 HMS2091B16 HMS502A15 HSDB 3234 IDI1_000653 KBio1_000653 KBio2_000877 KBio2_003445 KBio2_006013 KBio3_001627 KBioGR_001284 KBioSS_000877 L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine L-PAM L-Phenylalanine mustard L-Sarcolysin L-Sarcolysine L-Sarkolysin LS-15868 LS-865 | Levofalan Levofolan Levopholan M2011_SIGMA MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)) MLS001333666 MLS002153368 Melfalan Melfalano Melfalano [INN-Spanish] Melphalan (JP15/USP/INN) Melphalan [USAN:INN:BAN:JAN] Melphalanum Melphalanum [INN-Latin] Mephalan MolPort-003-665-535 NCGC00090757-01 NCGC00090757-02 NCGC00090757-03 NCI-C04853 NINDS_000653 NIOSH/AY3360000 NSC 241286 NSC 8806 NSC-8806 NSC241286 NSC8806 P-Di-(2-chloroethyl)amino-L-phenylalanine P-L-Sarcolysin P-N-Bis(2-chloroethyl)amino-L-phenylalanine Phenylalanine mustard Phenylalanine nitrogen mustard Prestwick_1006 RCRA waste no. U150 Rcra waste number U150 SK-15673 SMP2_000174 SMR000058720 SPBio_000287 SPECTRUM1500382 Sarcolysine Sarkolysin Spectrum2_000074 Spectrum3_000684 Spectrum4_000882 Spectrum5_001601 Spectrum_000397 TL8001065 TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN) TRANSGENIC MODEL EVALUATION (MELPHALAN) UNII-Q41OR9510P melphalan p-Bis(beta-chloroethyl)aminophenylalanine p-Di-(2-chloroethyl)amino-L-phenylalanine p-L-Sarcolysin p-L-sarcolysine p-N,N-bis(2-chloroethyl)amino-L-phenylalanine p-N-Bis(2-chloroethyl)amino-L-phenylalanine p-N-Di(chloroethyl)aminophenylalanine p-N-di(chloroethyl)aminophenylala nine phenylalanine nitrogen mu stard |
| | 2 | | Mesna | approved | Phase 3, Phase 1, Phase 2 | 263 | 3375-50-6 | 598 | 2-Mercaptoethane 2-Mercaptoethanesulfonate 2-Mercaptoethanesulfonic acid 2-mercaptoethanesulfonic acid 2-mercaptoethanesulphonic acid 2-mercaptoethylsulfonate 2-sulfanylethylsulfonate | CoM Coenzima M Coenzym M Coenzyme M HS-CoM reduced CoM reduced coenzyme M β-mercaptoethanesulfonic acid | |
| | 3 | | Cyclophosphamide | approved, investigational | Phase 3, Phase 2, Phase 1, Early Phase 1 | 2935 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Anhydrous cyclophosphamide Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 | DB00531 DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide |
| | 4 | | Etoposide | approved | Phase 3, Phase 1, Phase 2 | 1269 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin | Eposin, Vepesid, VP-16, Toposar, Etoposide Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide |
| | 5 | | Methotrexate | approved | Phase 3, Phase 2 | 1551 | 1959-05-2, 59-05-2 | 126941 | 4-amino-10-methylfolic acid 4-amino-N(10)-methylpteroylglutamic acid Abitrexate Amethopterin Amethopterine Antifolan Arbitrexate Emtexate Folex HDMTX L-Amethopterin Ledertrexate MTX Metatrexan | Methopterin Methotextrate Methotrate Methotrexat Methotrexate Sodium Methotrexatum Methylaminopterin Methylaminopterinum Metotrexato Mexate Méthotrexate N-Bismethylpteroylglutamic Acid N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid Rheumatrex Trexall | |
| | 6 | | Mechlorethamine | approved | Phase 3, Phase 2, Phase 1 | 397 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 | KBioGR_001448 KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 7 | | Cisplatin | approved | Phase 3, Phase 2 | 2770 | 15663-27-1 | 84093, 441203, 2767 | (SP-4-1)-diamminedichloridoplatinum (SP-4-1)-diamminedichloroplatinum (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Abiplatin Biocisplatinum Briplatin CACP CDDP CHEBI:35852 CID441203 CPD0-1392 CPDC CPDD Carboquone Cis Pt II Cis-DDP Cis-Diaminedichloroplatinum Cis-Diamminedichloroplatinum Cismaplat Cisplatine Cisplatino Cisplatinum Cisplatyl Citoplationo DB00515 DDP DDPT Diamminedichloroplatinum | EU-0100918 Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Plastin Platamine Platiblastin Platidiam Platinex Platinol Platinol-AQ Platinoxan Platinum Ammine Chloride Platinum Ammonium Chloride Platinum Diamine Dichloride Randa Trans-DDP Trans-Diaminedichloroplatinum Trans-Diamminedichloroplatinum Trans-Dichlorodiammine Platinum Trans-Platinumdiammine Dichloride cis-DDP cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) nchembio773-comp1 trans-diamminedichloridoplatinum(II) | |
| | 8 | | Busulfan | approved, investigational | Phase 3, Phase 1 | 545 | 55-98-1 | 2478 | 1, 4-Dimethanesulfonoxybutane 1, 4-Dimethylsulfonoxybutane 1, {4-Bis[methanesulfonoxy]butane} 1,4-BUTANEDIOL DIMETHANESULFONATE 1,4-Bis(methanesulfonoxy)butane 1,4-Bis(methanesulfonyloxy)butane 1,4-Bis[methanesulfonoxy]butane 1,4-Butanedi yl dimethanesulfonate 1,4-Butanediol dimethanesulfonate 1,4-Butanediol dimethanesulphonate 1,4-Butanediol dimethylsulfonate 1,4-Butanediol, dimethanesulfonate 1,4-Butanediol, dimethanesulphonate 1,4-Butanediyl dimethanesulfonate 1,4-Di(methylsulfonoxy)butane 1,4-Dimesyloxybutane 1,4-Dimethane sulfonyl oxybutane 1,4-Dimethanesulfonoxybutane 1,4-Dimethanesulfonoxylbutane 1,4-Dimethanesulfonyloxybutane 1,4-Dimethanesulphonyloxybutane 1,4-Dimethylsulfonoxybutane 1,4-Dimethylsulfonyloxybutane 2041 C. B 2041 C. B. 2041 C.B 2041 C.B. 4-((Methylsulfonyl)oxy)butyl methanesulfonate 4-methylsulfonyloxybutyl methanesulfonate 55-98-1 AC-198 AC1L1DRQ AC1Q4GRQ AI3-25012 AKOS003614975 AN 33501 Ambap55-98-1 B1022 B2635_FLUKA B2635_SIGMA BRN 1791786 BSPBio_001920 BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE) Bisulfex Busilvex Busulfan Busulfan (JP15/USP/INN) Busulfan GlaxoSmithKline Brand Busulfan Orphan Brand Busulfan Wellcome Busulfan Wellcome Brand Busulfan [INN:JAN] Busulfano Busulfano [INN-Spanish] Busulfanum Busulfanum [INN-Latin] Busulfex Busulphan Busulphane Butanedioldimethanesulfonate Buzulfan C.B. 2041 C6H14O6S2 CB 2041 CCRIS 418 CHEBI:28901 CHEMBL820 CID2478 CPD000058613 Citosulfan D002066 D00248 DB01008 DivK1c_000847 EINECS 200-250-2 FT-0083567 G.T. 41 GT 2041 GT 41 Glaxo Wellcome Brand of Busulfan GlaxoSmithKline Brand of Busulfan Glyzophrol HMS1920I07 HMS2091O09 HMS502K09 | HSDB 7605 I09-1371 IDI1_000847 InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3 KBio1_000847 KBio2_000512 KBio2_003080 KBio2_005648 KBio3_001420 KBioGR_000698 KBioSS_000512 LS-1358 Leucosulfan MLS001076666 MYLERAN (TN) Mablin Methanesulfonic Methanesulfonic acid, tetram ethylene ester Methanesulfonic acid, tetramethylene ester Mielevcin Mielosan Mielucin Milecitan Mileran Misulban Mitosan Mitostan MolPort-001-783-406 Myeleukon Myeloleukon Myelosan Myelosanum Mylecytan Myleran Myleran Tablets Myleran tablets Myleran, Busulfex, Busulfan Mylerlan NCGC00090905-01 NCGC00090905-02 NCGC00090905-03 NCGC00090905-04 NCGC00090905-05 NCGC00090905-06 NCGC00090905-07 NCI-C01592 NCI60_041640 NCIMech_000192 NINDS_000847 NSC 750 NSC-750 NSC-750sulphabutin NSC750 Orphan Brand of Busulfan Prestwick_989 S1692_Selleck SAM002554887 SMR000058613 SPBio_000253 SPECTRUM1500152 ST50825921 Spectrum2_000067 Spectrum3_000320 Spectrum4_000259 Spectrum5_000928 Spectrum_000092 Sulfabutin Sulfabutin (VAN) Sulphabutin Tetramethylene Dimethane Sulfonate Tetramethylene bis(methanesulfonate) Tetramethylene bis[methanesulfonate] Tetramethylene dimethane sulfonate Tetramethylene {bis[methanesulfonate]} Tetramethylenester Kyseliny Methansulfonove Tetramethylenester kyseliny methansulfonove Tetramethylenester kyseliny methansulfonove [Czech] UNII-G1LN9045DK WLN: WS1&O4OSW1 Wellcome Brand of Busulfan Wellcome, Busulfan X 149 acid, tetramethylene ester alkylating agent: crosslinks guanine residues busulfan butane-1,4-diyl dimethanesulfonate n-Butane-1,3-di(methylsulfonate) |
| | 9 | | Lenograstim | approved | Phase 3, Phase 2, Phase 1 | 1220 | 135968-09-1 | | G-CSF (CHO cell derived) Glycosylated recombinant G-CSF Glycosylated recombinant granulocyte colony stimulating factor | Granulocyte colony stimulating factor 3 (CHO cell derived) Granulocyte colony-stimulating factor lenograstim Lenograstim (genetical recombination) Lenograstim rDNA | |
| | 10 | | Vincristine | approved, investigational | Phase 3, Phase 2, Phase 1 | 922 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 11 | | Ifosfamide | approved | Phase 3, Phase 2, Phase 1 | 400 | 3778-73-2 | 3690 | (+-)-Ifosfamid (+-)-Ifosphamide (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide (D,L)-Ifosfamide (R,S)-Ifosphamide (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI) 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 3,} 2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 36341-88-5 3778-73-2 84711-20-6 A 4942 AB00513932 AC-2113 AC1L1GHW ASTA Z 4942 Ambap3778-73-2 Asta Z 4942 BPBio1_000865 BRN 0611835 BSPBio_000785 C07047 CAS-3778-73-2 CCRIS 352 CHEBI:5864 CHEMBL1024 CID3690 Cyfos D00343 D007069 DB01181 EINECS 223-237-3 HMS1570H07 HMS2090M12 HMS2093N07 HSDB 7023 Holoxan Holoxan 1000 I-Phosphamide I06-0494 IFEX (TN) Ifex Ifosfamid Ifosfamida Ifosfamida [INN-Spanish] Ifosfamide (JAN/USP/INN) | Ifosfamide Sterile Ifosfamide [USAN:INN:BAN:JAN] Ifosfamidum Ifosfamidum [INN-Latin] Ifosphamide Ifsofamide Iphosphamid Iphosphamid(e) Iphosphamide Iso Endoxan Iso-Endoxan Isoendoxan Isofosfamide Isophosphamide Isosfamide LS-102 LS-99799 MJF 9325 MJF-9325 MLS002154021 Mitoxana Mitoxana, Ifex, Ifosfamide MolPort-003-666-704 N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German] N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine NCGC00016639-01 NCGC00179435-01 NCI-C01638 NCI60_000233 NPFAPI-04 NSC 109,724 NSC 109724 NSC-109,724 NSC-109724 NSC109,724 NSC109724 Naxamide Prestwick0_000833 Prestwick1_000833 Prestwick2_000833 Prestwick3_000833 S1302_Selleck SMR001233348 SPBio_002706 STL058690 UNII-UM20QQM95Y WLN: T6NPOTJ AM2G BO B2G Z 4942 Z-4942 Z4942 ifosfamide isosfamide {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1, | |
| | 12 | | Doxorubicin | approved, investigational | Phase 3, Phase 2, Phase 1 | 1751 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 13 | | Zoledronic acid | approved | Phase 3, Phase 1 | 294 | 118072-93-8 | 68740 | (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate (1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid 118072-93-8 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid AC-1092 AC1L2ACJ AC1Q6RN3 AKOS005145739 Aclasta Anhydrous Zoledronic Acid BIDD:GT0292 BIDD:PXR0134 Bio-0112 Bisphosphonate 3 C088658 CGP 42'446 CGP 42446 CGP 42446A CGP-42'446 CGP-42446 CHEBI:46557 CHEMBL924 CID68740 D08689 DB00399 | FT-0082657 HMS2089O09 I06-0710 KS-1132 LS-181815 MolPort-002-885-874 MolPort-003-850-890 NCGC00159521-02 NCGC00159521-03 NSC721517 Novartis brand of zoledronic acid Reclast Reclast (TN) S00092 S1314_Selleck UNII-70HZ18PH24 ZOL Zol Zoledronate Zoledronic Acid Anhydrous Zoledronic Acid, Anhydrous Zoledronic acid Zoledronic acid (INN) Zoledronic acid [USAN:INN] Zometa Zometa (Novartis) Zometa (TN) Zometa Concentrate Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) | |
| | 14 | | Peginterferon alfa-2b | approved | Phase 3 | 307 | 99210-65-8, 215647-85-1 | | 215647-85-1 D02748 PEG-Intron PegIntron | Peginterferon alfa-2b Peginterferon alfa-2b (INN) Peginterferon alfa-2b (generical recombination) Peginterferon alfa-2b (generical recombination) (JAN) Pegintron (TN) Unitron PEG |
| | 15 | | leucovorin | approved, Nutraceutical | Phase 3, Phase 2 | 3235 | 58-05-9 | 54575, 6560146, 143 | (5-formyl-5,6,7,8-tetrahydropteroyl)glutamate (6R,S)-5-Formyltetrahydrofolate 10-Formyl-7,8-dihydrofolate 10-Formyl-7,8-dihydrofolic acid 5-Formyl-5,6,7,8-tetrahydrofolate 5-Formyl-5,6,7,8-tetrahydrofolic acid 5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid 5-Formyltetrahydrofolate 5-Formyltetrahydrofolic acid 5-Formyltetrahydropteroylglutamate 5-Formyltetrahydropteroylglutamic acid 5-formyltetrahydrofolic acid Acide folinique Calcium citrovorum factor Calcium folinate Citrovorum factor Folinate Folinic acid Folinic acid calcium salt | Folinic acid calcium salt USP27 Folinic acid-SF L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid L-Leucovorin L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid L-leucovorin Leucal Leucovorin calcium Leucovorin folinic acid Leucovorinum Leukovorin Levoleucovorin N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid N5-Formyl-5,6,7,8-tetrahydrofolate N5-Formyl-5,6,7,8-tetrahydrofolic acid N5-Formyl-THF N5-Formyltetrahydrofolate N5-Formyltetrahydrofolic acid Welcovorin Wellcovorin folinate |
| | 16 | | Folic Acid | approved, nutraceutical, vet_approved | Phase 3, Phase 2, Phase 1 | 4392 | 59-30-3 | 6037 | (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid 01769_FLUKA 2d0k 33609-88-0 36653-55-1 (mono-potassium salt) 59-30-3 6484-89-5 (mono-hydrochloride salt) AC-11682 AC1L1LNX AI3-26387 AKOS000503224 ARONIS014410 Acfol (Spain) Acide folique Acide folique [INN-French] Acido folico Acido folico [INN-Spanish] Acidum folicum Acidum folicum [INN-Latin] Acifolic Antianemia factor Apo-Folic BIDD:ER0563 BIDD:GT0641 BIF0608 BPBio1_000654 BSPBio_000594 BSPBio_002338 C00504 C20H20N6O6 CAS-59-30-3 CCRIS 666 CHEBI:27470 CHEMBL1622 CID6037 CPD000471860 Cytofol D00070 DB00158 DivK1c_000494 Dosfolat B activ EINECS 200-419-0 F0043 F7876_SIAL F7876_SIGMA F8758_SIGMA F8798_SIAL F8890_SIGMA FOL Facid Factor U Folacid Folacin Folaemin Folaemin [Netherlands] Folan Folasic (Australia) Folate Folbal Folcidin Folcidin (VAN) Folcysteine Foldine Foldine [France] Folettes Foliamin Folic Folic acid Folic acid (JP15/USP/INN) Folic acid (TN) Folic acid [BAN:INN:JAN] Folic acid [INN:BAN:JAN] Folic acid dihydrate Folicet Folicet (TN) Folico Folico (Italy) Folina Folina (Italy) Folipac Folsaeure | Folsan Folsaure Folsav Folvite Folvron Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L HMS1921D20 HMS2092N17 HMS501I16 HSDB 2002 IDI1_000494 InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s Incafolic KBio1_000494 KBio2_001861 KBio2_004429 KBio2_006997 KBio3_001558 KBioGR_002222 KBioSS_001861 Kyselina listova Kyselina listova [Czech] LS-2157 Liver Lactobacillus casei factor MLS001304016 MLS001335861 Millafol Mission prenatal Mittafol MolPort-004-285-551 N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-Pteroyl-L-glutamic acid N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid NCGC00016265-01 NCGC00142391-01 NINDS_000494 NSC 3073 Nifolin Nifolin [Denmark] Novofolacid Novofolacid [Canada] PGA PGA (VAN) Prestwick3_000627 Prestwick_230 PteGlu Pteroyl-L-glutamate Pteroyl-L-glutamic acid Pteroyl-L-monoglutamate Pteroyl-L-monoglutamic acid Pteroylglutamate Pteroylglutamic acid Pteroylmonoglutamate Pteroylmonoglutamic acid SAM002264616 SDCCGMLS-0066738.P001 SMP2_000137 SMR000471860 SPBio_001357 SPECTRUM1502020 Serum Folate Level Spectrum2_001459 Spectrum3_000749 Spectrum4_001751 Spectrum5_000602 Spectrum_001381 UNII-935E97BOY8 Usaf cb-13 Vitamin B11 Vitamin B9 Vitamin Bc Vitamin Be Vitamin M bmse000299 folic acid nchembio.108-comp10 | |
| | 17 | | Doxil | Approved June 1999 | Phase 3, Phase 2, Phase 1 | 1751 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 18 | | Antineoplastic Agents, Alkylating | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 4603 | | | | 19 | | Alkylating Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 4827 | | | | 20 | | Adjuvants, Immunologic | | Phase 3, Phase 2, Phase 1 | 2554 | | | | 21 | | Anti-Bacterial Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 11226 | | | | 22 | | Antibiotics, Antitubercular | | Phase 3, Phase 2, Phase 1 | 7180 | | | | 23 | | Protective Agents | | Phase 3, Phase 2 | 7443 | | | | 24 | | Antiviral Agents | | Phase 3, Phase 2, Phase 1 | 9967 | | | | 25 | | Etoposide phosphate | | Phase 3, Phase 1, Phase 2 | 1269 | | | | 26 | | Immunosuppressive Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 13086 | | | | 27 | | Anti-Infective Agents | | Phase 3, Phase 2, Phase 1, Early Phase 1 | 22062 | | | | 28 | | Antirheumatic Agents | | Phase 3, Phase 1, Phase 2, Early Phase 1 | 10956 | | | | 29 | | Antibodies, Monoclonal | | Phase 3, Phase 1, Phase 2 | 4039 | | | | 30 | | Bone Density Conservation Agents | | Phase 3, Phase 2, Phase 1 | 3376 | | | | 31 | | interferons | | Phase 3, Phase 1 | 2175 | | | | 32 | | Immunoglobulins | | Phase 3, Phase 2, Phase 1 | 6394 | | | | 33 | | Antibodies | | Phase 3, Phase 2, Phase 1 | 6394 | | | | 34 | | razoxane | | Phase 3 | 43 | | | | 35 | | Folic Acid Antagonists | | Phase 3, Phase 2 | 2257 | | | | 36 | | Antimitotic Agents | | Phase 3, Phase 2, Phase 1 | 5657 | | | | 37 | | Antimetabolites, Antineoplastic | | Phase 3, Phase 2, Phase 1 | 7361 | | | | 38 | | Dermatologic Agents | | Phase 3, Phase 2 | 5806 | | | | 39 | | Antineoplastic Agents, Phytogenic | | Phase 3, Phase 2, Phase 1 | 5602 | | | | 40 | | Nucleic Acid Synthesis Inhibitors | | Phase 3, Phase 2 | 4962 | | | | 41 | | Isophosphamide mustard | | Phase 3, Phase 2, Phase 1 | 400 | | | | 42 | | Topoisomerase Inhibitors | | Phase 3, Phase 2, Phase 1 | 5069 | | | | 43 | | Vitamin B Complex | | Phase 3, Phase 2, Phase 1 | 4337 | | | | 44 | | Antimetabolites | | Phase 3, Phase 2, Phase 1 | 12054 | | | | 45 | | Podophyllotoxin | | Phase 3 | 61 | 518-28-5 | | | 46 | | Keratolytic Agents | | Phase 3 | 444 | | | | 47 | | Treosulfan | | Phase 3 | 32 | 299-75-2 | 9296 | (2S,3S)-Threitol 1,4-bismethanesulfonate 1,4-Dimethanesulfonate(2S,3S)-Threitol 1,4-DimethanesulfonateL-(+ )-Threitol 1,4-DimethanesulfonateL-Threitol DHB Dihydroxybusulfan | Dihydroxymyleran L-Threitol 1,4-dimethanesulfonate L-Threitol, 1, 4-bis(methanesulfonate) L-Threitol-1, 4-bis(methanesulfonate) L-Threitol-1,4-bis(methanesulfonate) L-Threityl dimesylate Tresulfan | |
| | 48 | | Diphosphonates | | Phase 3, Phase 1 | 450 | | | | 49 | | Interferon-alpha | | Phase 3 | 1152 | | | | 50 | | Folate | Nutraceutical | Phase 3, Phase 2, Phase 1 | 4392 | | |
Interventional clinical trials: (show top 50)
(show all 95)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study | Completed | NCT00001217 | Phase 3 | | 2 | Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma | Completed | NCT00003937 | Phase 3 | | 3 | Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor | Completed | NCT00006734 | Phase 3 | | 4 | Study in Localized and Disseminated Ewing Sarcoma | Recruiting | NCT00987636 | Phase 3 | | 5 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | Recruiting | NCT02180867 | Phase 2, Phase 3 | | 6 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma | Recruiting | NCT02306161 | Phase 3 | | 7 | Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma | Active, not recruiting | NCT00134030 | Phase 3 | | 8 | Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma | Unknown status | NCT01216826 | Phase 2 | | 9 | Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | Unknown status | NCT00179816 | Phase 1, Phase 2 | | 10 | Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas | Unknown status | NCT00998361 | Phase 2 | | 11 | Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies | Completed | NCT00038207 | Phase 2 | | 12 | Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy | Completed | NCT00035620 | Phase 2 | | 13 | Clinical Studies of Gemcitabine-Oxaliplatin | Completed | NCT00407433 | Phase 2 | | 14 | A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) | Completed | NCT02441309 | Phase 2 | | 15 | Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | Completed | NCT00024258 | Phase 2 | | 16 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | Completed | NCT01288573 | Phase 1, Phase 2 | | 17 | A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas | Completed | NCT00001564 | Phase 2 | | 18 | A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas | Completed | NCT00001566 | Phase 2 | | 19 | Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma | Completed | NCT00006102 | Phase 2 | | 20 | Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor | Completed | NCT00055952 | Phase 2 | | 21 | Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas | Completed | NCT00165139 | Phase 2 | | 22 | Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas | Completed | NCT00003745 | Phase 2 | | 23 | Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma | Completed | NCT02546544 | Phase 2 | | 24 | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | Recruiting | NCT02470091 | Phase 2 | | 25 | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | Recruiting | NCT03006848 | Phase 2 | | 26 | Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity | Recruiting | NCT02273583 | Phase 2 | | 27 | To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | Recruiting | NCT01962103 | Phase 1, Phase 2 | | 28 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | Recruiting | NCT02945800 | Phase 2 | | 29 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | Recruiting | NCT02689336 | Phase 2 | | 30 | Methionine PET/CT Studies In Patients With Cancer | Recruiting | NCT00840047 | Phase 2 | | 31 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | Recruiting | NCT02541604 | Phase 1, Phase 2 | | 32 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | Recruiting | NCT02624388 | Phase 2 | | 33 | A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma | Recruiting | NCT02748135 | Phase 1, Phase 2 | | 34 | Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | Recruiting | NCT02574728 | Phase 2 | | 35 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | Recruiting | NCT01864109 | Phase 2 | | 36 | A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma | Recruiting | NCT02511132 | Phase 2 | | 37 | Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma | Active, not recruiting | NCT01650090 | Phase 2 | | 38 | A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung | Active, not recruiting | NCT00752206 | Phase 2 | | 39 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | Active, not recruiting | NCT01614795 | Phase 2 | | 40 | A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | Active, not recruiting | NCT00667342 | Phase 2 | | 41 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | Active, not recruiting | NCT01807468 | Phase 2 | | 42 | Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma | Active, not recruiting | NCT02487979 | Phase 2 | | 43 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | Active, not recruiting | NCT00788125 | Phase 1, Phase 2 | | 44 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | Active, not recruiting | NCT00923351 | Phase 1, Phase 2 | | 45 | Radiation Therapy to Treat Musculoskeletal Tumors | Active, not recruiting | NCT00186992 | Phase 2 | | 46 | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma | Suspended | NCT02484443 | Phase 2 | | 47 | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | Terminated | NCT01313884 | Phase 2 | | 48 | Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma | Unknown status | NCT00101309 | Phase 1 | | 49 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | Completed | NCT01169584 | Phase 1 | | 50 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | Completed | NCT00093821 | Phase 1 |
|
